Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745941 | 0.94 | ALDH1A1 (0.36) | ALDH1A1CYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL4745959 | 0.89 | CYP1A2 (0.35) | ALDH1A1CYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL4745880 | 0.89 | MAPT (0.34) | ALDH1A1L3MBTL1 | |
| SCHEMBL4746394 | 0.88 | MEN1 (0.32) | ALDH1A1CYP1A2CCR1CCR8 | |
| SCHEMBL4745860 | 0.88 | MAOA (0.35) | ALDH1A1CYP1A2CYP2A6CCR1CCR8 | |
| SCHEMBL4746409 | 0.87 | PDK2 (0.33) | ALDH1A1CYP1A2CCR1CCR8L3MBTL1 | |
| SCHEMBL4745945 | 0.86 | HPRT1 (0.37) | ALDH1A1CYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL4746108 | 0.85 | CCR1 (0.39) | ALDH1A1CYP1A2CCR1CCR5CCR8 | |
| SCHEMBL4746272 | 0.85 | MAPT (0.32) | CCR1CCR8 | |
| SCHEMBL4745912 | 0.85 | TGFBR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | NR2E3, OR51E2, AZI2 | ALDH1A1 179/4885CYP1A2 56/4885CYP2A6 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.